{
    "Clinical Trial ID": "NCT01663727",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Paclitaxel+Placebo",
        "  Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.",
        "INTERVENTION 2: ",
        "  Paclitaxel+ Bevacizumab",
        "  Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed, HER2-negative adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.",
        "  ECOG performance status of 0 or 1",
        "  For women of childbearing potential, use of an acceptable and effective method of non-hormonal contraception",
        "  For patients who have received recent radiotherapy, recovery prior to randomization from any significant acute toxicity, and radiation treatments have to be completed more than 3 weeks from randomization",
        "Exclusion Criteria:",
        "  Disease-Specific Exclusions:",
        "  HER2-positive status",
        "  Prior chemotherapy for locally recurrent or metastatic disease",
        "  Prior hormonal therapy < 2 weeks prior to randomization",
        "  Prior adjuvant or neo-adjuvant chemotherapy is allowed, provided its conclusion has been for at least 12 months prior to randomization",
        "  Investigational therapy within 28 days of randomization",
        "  General Medical Exclusions:",
        "  Life expectancy of < 12 weeks",
        "  Inadequate organ function",
        "  Uncontrolled serious medical or psychiatric illness",
        "  Active infection requiring intravenous (IV) antibiotics at screening",
        "  Pregnancy or lactation",
        "  History of other malignancies within 5 years prior to screening, except for tumors with a negligible risk for metastasis or death"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Progression or Death in Intent-to-Treat (ITT) Population",
        "  Tumor assessment was performed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator. Disease progression was defined as at least 20 percent (%) increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), unequivocal progression of existing non-target lesions, or presence of new lesions.",
        "  Time frame: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)",
        "Results 1: ",
        "  Arm/Group Title: Paclitaxel+Placebo",
        "  Arm/Group Description: Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.",
        "  Overall Number of Participants Analyzed: 242",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  69.4",
        "Results 2: ",
        "  Arm/Group Title: Paclitaxel+ Bevacizumab",
        "  Arm/Group Description: Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.",
        "  Overall Number of Participants Analyzed: 239",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  63.6"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 45/233 (19.31%)",
        "  Anaemia * 2/233 (0.86%)",
        "  Febrile neutropenia * 0/233 (0.00%)",
        "  Leukopenia * 1/233 (0.43%)",
        "  Neutropenia * 1/233 (0.43%)",
        "  Atrial fibrillation * 1/233 (0.43%)",
        "  Left ventricular dysfunction * 0/233 (0.00%)",
        "  ACUTE CORONARY SYNDROME * 0/233 (0.00%)",
        "  CARDIAC FAILURE CONGESTIVE * 1/233 (0.43%)",
        "  Optic nerve disorder * 1/233 (0.43%)",
        "Adverse Events 2:",
        "  Total: 66/238 (27.73%)",
        "  Anaemia * 1/238 (0.42%)",
        "  Febrile neutropenia * 4/238 (1.68%)",
        "  Leukopenia * 1/238 (0.42%)",
        "  Neutropenia * 0/238 (0.00%)",
        "  Atrial fibrillation * 0/238 (0.00%)",
        "  Left ventricular dysfunction * 1/238 (0.42%)",
        "  ACUTE CORONARY SYNDROME * 1/238 (0.42%)",
        "  CARDIAC FAILURE CONGESTIVE * 0/238 (0.00%)",
        "  Optic nerve disorder * 0/238 (0.00%)"
    ]
}